[1]Patent:EP1690852,2006,A1.Locationinpatent:Page/Pagecolumn17
[1]Patent:WO2006/134489,2006,A1.Locationinpatent:Page/Pagecolumn15
[1]Patent:WO2006/134489,2006,A1.Locationinpatent:Page/Pagecolumn20
[1]EuropeanJournalofMedicinalChemistry,2009,vol.44,p.1959-1971
Title: Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10.
Journal: Chemico-biological interactions 20150605
Title: Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis.
Journal: Photochemistry and photobiology 20120901
Title: A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis.
Journal: Urology 20120801
Title: Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines.
Journal: Medical oncology (Northwood, London, England) 20120601
Title: The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.
Journal: FEBS letters 20120102
Title: Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Journal: Prostaglandins & other lipid mediators 20111101
Title: Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20110801
Title: Studies on the metabolism and biological activity of the epimers of sulindac.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110601
Title: Optimisation and validation of a fast HPLC method for the quantification of sulindac and its related impurities.
Journal: Journal of pharmaceutical and biomedical analysis 20110325
Title: [Antitumor effects of sulindac in ovarian cell cultures].
Journal: Ginekologia polska 20110301
Title: Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.
Journal: PloS one 20110101
Title: Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
Journal: European journal of medicinal chemistry 20101101
Title: Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.
Journal: The Journal of pharmacology and experimental therapeutics 20100801
Title: Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor.
Journal: Cancer prevention research (Philadelphia, Pa.) 20100401
Title: Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer.
Journal: Expert opinion on investigational drugs 20100401
Title: Sulindac sulfone induces a decrease of beta-catenin in HNSCC.
Journal: Anticancer research 20100201
Title: 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.
Journal: Archives of biochemistry and biophysics 20090715
Title: Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.
Journal: European journal of medicinal chemistry 20090501
Title: A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201
Title: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901
Title: A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Journal: Clinical genitourinary cancer 20080901
Title: Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1.
Journal: Cancer research 20080701
Title: Interactions of sulindac and its metabolites with phospholipid membranes: an explanation for the peroxidation protective effect of the bioactive metabolite.
Journal: Free radical research 20080701
Title: Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Journal: Journal of medicinal chemistry 20080612
Title: The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB.
Journal: Oncogene 20080417
Title: Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells.
Journal: International journal of cancer 20080301
Title: A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
Journal: Cancer chemotherapy and pharmacology 20080201
Title: Malignant transformation of normal enterocytes following downregulation of Bak expression.
Journal: Digestion 20080101
Title: Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20071001
Title: Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071001
Title: Sulindac sulfone modulates beta-catenin in human cholesteatoma cell culture.
Journal: Archives of medical research 20070501
Title: Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon.
Journal: Cancer research 20070401
Title: Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis.
Journal: Apoptosis : an international journal on programmed cell death 20070201
Title: Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition.
Journal: Cancer biology & therapy 20070101
Title: Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.
Journal: Chemico-biological interactions 20061201
Title: Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.
Journal: Biochemical pharmacology 20061115
Title: Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
Journal: British journal of haematology 20061101
Title: p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis.
Journal: Oncology reports 20061101
Title: 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Journal: Prostaglandins & other lipid mediators 20061001
Title: A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901
Title: Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer.
Journal: Oncology reports 20060801
Title: Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
Journal: American journal of clinical oncology 20060801
Title: Capillary electrophoresis combining field-amplified sample stacking and electroosmotic flow suppressant for analysis of sulindac and its two metabolites in plasma.
Journal: Journal of chromatography. A 20060630
Title: Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060601
Title: Apoptosis: a relevant tool for anticancer therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20060601
Title: Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells.
Journal: Molecular cancer therapeutics 20060501
Title: The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Journal: Bioorganic & medicinal chemistry letters 20060415
Title: Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.
Journal: Gut 20060301
Title: Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301
Title: Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells.
Journal: The Biochemical journal 20060215
Title: Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
Journal: Investigational new drugs 20060101
Title: The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization.
Journal: Molecular cancer therapeutics 20060101
Title: Exisulind in the treatment of prostate cancer.
Journal: Expert review of anticancer therapy 20051201
Title: Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC.
Journal: Annals of the New York Academy of Sciences 20051101
Title: Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.
Journal: Cancer research 20050915
Title: Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20050701
Title: The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
Journal: Cell cycle (Georgetown, Tex.) 20050601
Title: A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
Journal: BJU international 20050501
Title: A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Journal: Clinical lung cancer 20050501
Title: Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.
Journal: Molecular cancer therapeutics 20050201
Title: Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells.
Journal: Bioscience, biotechnology, and biochemistry 20050201
Title: Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
Journal: Cancer research 20041115
Title: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20041115
Title: A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20041101
Title: Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone.
Journal: International journal of molecular medicine 20041001
Title: Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid.
Journal: Gastroenterology 20040801
Title: Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells.
Journal: British journal of cancer 20040705
Title: Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells.
Journal: Cancer research 20040601
Title: Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Journal: Drugs in R&D 20040101
Title: Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci.
Journal: Anticancer research 20040101
Title: Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells.
Journal: Apoptosis : an international journal on programmed cell death 20031201
Title: Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.
Journal: The Journal of biological chemistry 20031128
Title: The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species.
Journal: Free radical biology & medicine 20031101
Title: Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20031015
Title: Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915
Title: Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells.
Journal: Molecular cancer therapeutics 20030901
Title: Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Journal: Molecular cancer therapeutics 20030501
Title: Chemoprevention of colorectal cancer: slow, steady progress.
Journal: Cleveland Clinic journal of medicine 20030401
Title: What's new in the treatment of advanced prostate cancer?
Journal: European journal of cancer (Oxford, England : 1990) 20030101
Title: Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.
Journal: Journal of experimental therapeutics & oncology 20030101
Title: Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation.
Journal: Biochemical pharmacology 20021101
Title: Rapid development of colitis in NSAID-treated IL-10-deficient mice.
Journal: Gastroenterology 20021101
Title: Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
Journal: Cancer research 20021015
Title: Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G.
Journal: Molecular cancer therapeutics 20020801
Title: Sulindac derivative-induced apoptosis in a human umbilical vein endothelial cell line ECV304.
Journal: Chinese medical journal 20020701
Title: Novel clinical trials in androgen-independent prostate cancer.
Journal: Clinical prostate cancer 20020601
Title: PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells.
Journal: International journal of cancer 20020420
Title: Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
Journal: The Journal of biological chemistry 20020419
Title: CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells.
Journal: Molecular cancer therapeutics 20020401
Title: Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020301
Title: GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells.
Journal: Cancer research 20020215
Title: Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Journal: Seminars in oncology 20020201
Title: Sulindac induces apoptosis, inhibits proliferation and activates caspase-3 in Hep G2 cells.
Journal: Anticancer research 20020101
Title: beta-Catenin signaling: therapeutic strategies in oncology.
Journal: Cancer biology & therapy 20020101
Title: Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II.
Journal: Melanoma research 20011201
Title: Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.
Journal: The Journal of pharmacology and experimental therapeutics 20011101
Title: Exisulind, a selective apoptotic antineoplastic drug.
Journal: Expert opinion on investigational drugs 20011001
Title: Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.
Journal: Cancer research 20010915
Title: Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
Journal: The Journal of urology 20010901
Title: Docetaxel and exisulind in hormone-refractory prostate cancer.
Journal: Seminars in oncology 20010801
Title: Sulindac-associated choledocholithiasis.
Journal: The American journal of gastroenterology 20010701
Title: Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.
Journal: Carcinogenesis 20010601
Title: Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Journal: Cancer research 20010515
Title: Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1.
Journal: The Journal of biological chemistry 20010511
Title: Sulindac and its derivatives: a novel class of anticancer agents.
Journal: Current opinion in investigational drugs (London, England : 2000) 20010501
Title: Proapoptotic anti-inflammatory drugs.
Journal: Urology 20010401
Title: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
Journal: Cancer research 20010215
Title: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Journal: Cancer research 20010215
Title: Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac.
Journal: International journal of cancer 20001215
Title: Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.
Journal: Cancer research 20001201
Title: Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.
Journal: Journal of gastroenterology and hepatology 20001201
Title: Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20001001
Title: Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Journal: Cancer research 20000701
Title: Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20000201
Title: Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
Journal: Cancer research 19990715
